IBA and Eczacıbaşı-Monrol Join Forces to Grow Market for Radiopharmaceuticals in Several Regions

IBA and Eczacıbaşı-Monrol join forces to Grow market for

Radiopharmaceuticals in several regions

 

February 6, 2009

 

Louvain-la-Neuve, Belgium and Gebze, Turkey, February 6, 2009 – IBA (Ion Beam Applications S.A.) and Eczacıbaşı-Monrol Nuclear Products A.S. are joining forces to grow the market for PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography)Radiopharmaceuticals in the Balkans, Middle East, North Africa, Central and Eastern Europe.

 

The Memorandum of Understanding signed today calls for IBA and Eczacıbaşı-Monrol to join forces for the distribution and sale of IBA diagnostic and therapy SPECT radiopharmaceuticals and new molecules in PET Radiopharmaceuticals. Eczacıbaşı-Monrol  will be appointed by IBA as the preferred partner for the local distribution of the IBA diagnostic and therapy SPECT radiopharmaceuticals and new molecules in PET Radiopharmaceuticals, and to enhance the development of Nuclear Medicine in the Balkans, Middle East,North Africa, Central and Eastern Europe. Both companies will also work in close cooperation in those regions on the operation of high energy cyclotrons for diagnostics and therapy isotopes manufacturing.

 

Eczacıbaşı-Monrol plans to invest in 3 more PET radiopharmaceutical (FDG – Fluorodeoxyglucose) production centers on its own to complement its existing 5 cyclotrons network, which means that IBA’s PET Radiopharmaceuticals production and distribution network will be supported by a total of 52 facilities worldwide. IBA is not investing in these Eczacıbaşı-Monrol facilities and they will not contribute directly to IBA’s financial statement.

 

IBA can now leverage the largest network of PET Radiopharmaceuticals production and distribution centers in the world, which will be essential to support the launch of new molecules in the PET market.

 

“We are pleased about this strategic partnership with Eczacıbaşı-Monrol the leader in Nuclear Medicine inTurkey”, said Pierre Mottet, Chief Executive Officer of IBA. “This partnership is an important milestone in the expansion of our leading position in the field of Radiopharmaceutical products; it further strengthens our presence in the world. We very much look forward to our enhanced cooperation", continued Mr. Mottet.

 

  “This strategic partnership will strongly contribute to one of the key strategies of Eczacıbaşı-Monrol, which is to bring new Radiopharmaceutical products to the Nuclear Medicine Society of Turkey and the Region. We strongly believe that this partnership will strengthen our leading position in Turkey and will be an important milestone to further strengthen our position in the Region both with SPECT and PET products “, said Sedat Birol, Executive Vice President of the Eczacıbaşı Healthcare Division.

 

 

 

 

About Eczacıbaşı-Monrol

ECZACIBASI-MONROL Nuclear Products Co. develops and sells SPECT and PET radiopharmaceuticals and operates FDG centers in the Region. It is strategically targeting to expand its radiopharmaceuticals network of cyclotrons through additional investments in Turkey and the Region.

 

 

Contact

ECZACIBASI-MONROL Nuclear Products Co.

Köksal Ülgen

Business Development Manager

Phone: +90 262 648 02 04

koksal.ulgen@monrol.com

 

 

 

About IBA

IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index.

(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Website: http://www.iba-worldwide.com

 

Contact

IBA

Paul-Emmanuel Goethals

Director, Corporate Business Development

 & Investor Relations

Phone: +32 10 47 58 16

paul-emmanuel.goethals@iba-group.com

Tüm Haberlere Git